Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of AML or MDS~* Patients not in remission at the time of transplant~* Age 18-75~* ECOG performance status \<2~* Availability of a family HLA haploidentical donor, eligible to donate both marrow cells and unstimulated lymphocytes (1 apheresis procedure at day +7) .~Exclusion Criteria:~* Positive serologic markers for human immunodeficiency virus (HIV)~* Acute hepatitis B virus (HBV) or acute hepatitis C virus (HCV) infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Haplo-stem cell transplant followed by NK infusion (Type: EXPERIMENTAL): Haplo stem cell transplant (from bone marrow or apheresis) is followed by a haplo-NK cell infusion (target dose ≥1\*106/kg b.w.) at day 7.~Unstimulated haplo-NK cells are collected through apheresis Mononuclear cells are then subjected to a preliminary negative selection of CD3+ cells and to a subsequent positive selection of CD56+ cells. CD3 negative/CD56 positive cells are infused
- Haplo-stem cell transplant (Type: ACTIVE_COMPARATOR): Patients in this arm receive standard haplo stem cell transplant (from bone marrow or apheresis) transplant without subsequent NK cell infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).